Raymond James raised the firm’s price target on Knight Therapeutics (KHTRF) to C$8 from C$7.50 and keeps an Outperform rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback